SEC Form 4 · accession 0001225208-18-016168
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Xin Warren Wang
Officer — SVP and Pres, Asia Pacific
Period of report
Dec 1, 2018
Accepted (ET)
Dec 4, 2018 · 4:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 1, 2018 | M | 2,025 | $0.00 | A | 97,573 | D | |
| Common StockF2 | Dec 1, 2018 | F | 912 | $37.67 | D | 96,661 | D | |
| Common StockF4,F2 | Dec 3, 2018 | S | 10,000 | $37.9994 | D | 86,661 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Stock UnitsF1,F5 | — | Dec 1, 2018 | M | 2,025 | D | — | Dec 1, 2020 | Common Stock | 2,025 | 4,050 | D |
Explanation of responses
- F1Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- F2Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
- F3This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.
- F4Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.8201 to $38.20, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2016, the first anniversary of the date of grant.